[go: up one dir, main page]

AR117653A1 - Método para tratamiento de miastenia grave - Google Patents

Método para tratamiento de miastenia grave

Info

Publication number
AR117653A1
AR117653A1 ARP190102931A ARP190102931A AR117653A1 AR 117653 A1 AR117653 A1 AR 117653A1 AR P190102931 A ARP190102931 A AR P190102931A AR P190102931 A ARP190102931 A AR P190102931A AR 117653 A1 AR117653 A1 AR 117653A1
Authority
AR
Argentina
Prior art keywords
treatment
myastenia
grave
antigen
prevention
Prior art date
Application number
ARP190102931A
Other languages
English (en)
Inventor
Manis Elizabeth Webster
Grant Langdon
Claus Peter Kiessling
Bernhard Heinrich Greve
William James Byrnes
Melissa Kaye Brock
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Publication of AR117653A1 publication Critical patent/AR117653A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La descripción se refiere a un método para el tratamiento o la prevención de la miastenia grave (MG) en un ser humano que lo necesita, usando un anticuerpo anti-FcRn o su fragmento de unión al antígeno. En particular, el método proporciona regímenes de dosificación para dicho tratamiento.
ARP190102931A 2018-10-16 2019-10-16 Método para tratamiento de miastenia grave AR117653A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862746174P 2018-10-16 2018-10-16

Publications (1)

Publication Number Publication Date
AR117653A1 true AR117653A1 (es) 2021-08-25

Family

ID=68290236

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190102931A AR117653A1 (es) 2018-10-16 2019-10-16 Método para tratamiento de miastenia grave

Country Status (13)

Country Link
US (1) US20220144941A1 (es)
EP (1) EP3866933A1 (es)
JP (2) JP7518821B2 (es)
CN (1) CN113646051A (es)
AR (1) AR117653A1 (es)
AU (1) AU2019361247B2 (es)
BR (1) BR112021007092A2 (es)
CA (1) CA3116091A1 (es)
IL (1) IL282137A (es)
MA (1) MA53903A (es)
MX (1) MX2021004351A (es)
SG (1) SG11202103801UA (es)
WO (1) WO2020079086A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7420720B2 (ja) 2017-12-13 2024-01-23 モメンタ ファーマシューティカルズ インコーポレイテッド ＦｃＲｎ抗体およびその使用方法
CR20210076A (es) 2018-07-20 2021-09-02 Momenta Pharmaceuticals Inc Composiciones de anticuerpo fcrn
CA3200972A1 (en) * 2020-11-06 2022-05-12 Momenta Pharmaceuticals, Inc. Fcrn antibodies and methods of use thereof
JP2025512483A (ja) 2022-04-13 2025-04-17 オーエスイー・イミュノセラピューティクス 抗体を選択的に排除するための分子の新規のクラス
AU2023264039A1 (en) * 2022-05-05 2024-11-07 Ra Pharmaceuticals, Inc. Treatment of myasthenia gravis with zilucoplan
JP2025519559A (ja) * 2022-06-11 2025-06-26 インヒブルクス バイオサイエンシズ インコーポレイテッド ＦｃＲｎ結合ポリペプチド及びその使用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9113120D0 (en) 1991-06-18 1991-08-07 Kodak Ltd Photographic processing apparatus
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
GB0129105D0 (en) 2001-12-05 2002-01-23 Celltech R&D Ltd Expression control using variable intergenic sequences
WO2004051268A1 (en) 2002-12-03 2004-06-17 Celltech R & D Limited Assay for identifying antibody producing cells
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
JP2007536898A (ja) 2003-07-01 2007-12-20 セルテック アール アンド ディ リミテッド 修飾抗体Ｆａｂフラグメント
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
CA2606378A1 (en) 2005-04-29 2006-11-09 The Jackson Laboratory Fcrn antibodies and uses thereof
MY169746A (en) 2005-08-19 2019-05-14 Abbvie Inc Dual variable domain immunoglobulin and uses thereof
WO2007087289A2 (en) 2006-01-25 2007-08-02 The Research Foundation Of State University Of New York Anti-fcrn antibodies for treatement of auto/allo immune conditions
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
ES2667729T3 (es) 2007-09-26 2018-05-14 Ucb Biopharma Sprl Fusiones de anticuerpos con doble especificidad
US8273351B2 (en) 2008-04-25 2012-09-25 Dyax Corp. Fc receptor binding proteins
HUE033438T2 (en) 2008-09-26 2017-11-28 Ucb Biopharma Sprl Biological products
KR101730675B1 (ko) 2009-07-14 2017-05-11 웨이브텍 비젼 시스템스, 인크. 안과 수술 측정 시스템
WO2011030107A1 (en) 2009-09-10 2011-03-17 Ucb Pharma S.A. Multivalent antibodies
GB0920127D0 (en) 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
GB201320066D0 (en) 2013-11-13 2013-12-25 Ucb Pharma Sa Biological products
SG11201608208VA (en) 2014-04-30 2016-11-29 Hanall Biopharma Co Ltd Antibody binding to fcrn for treating autoimmune diseases
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
SMT202300365T1 (it) 2015-01-30 2023-11-13 Momenta Pharmaceuticals Inc Anticorpi fcrn e loro metodi di utilizzo
GB201610198D0 (en) * 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
MX2020005981A (es) * 2017-12-08 2020-08-24 Argenx Bvba Uso de antagonistas del fcrn para el tratamiento de la miastenia gravis generalizada.

Also Published As

Publication number Publication date
CA3116091A1 (en) 2020-04-23
US20220144941A1 (en) 2022-05-12
WO2020079086A1 (en) 2020-04-23
SG11202103801UA (en) 2021-05-28
MA53903A (fr) 2021-08-25
JP2022512713A (ja) 2022-02-07
AU2019361247A1 (en) 2021-05-27
JP7518821B2 (ja) 2024-07-18
KR20210078517A (ko) 2021-06-28
BR112021007092A2 (pt) 2021-08-03
EP3866933A1 (en) 2021-08-25
JP2024138363A (ja) 2024-10-08
IL282137A (en) 2021-05-31
MX2021004351A (es) 2021-05-31
AU2019361247B2 (en) 2025-06-26
CN113646051A (zh) 2021-11-12

Similar Documents

Publication Publication Date Title
AR117653A1 (es) Método para tratamiento de miastenia grave
EP4327866A3 (en) Mirikizumab in the treatment of ulcerative colitis
CO2020004831A2 (es) Dosis y administración de anticuerpos antic-c5 para el tratamiento de pacientes con glomerulonefritis membranoproliferativa
CL2019001265A1 (es) Variantes de il-2 para el tratamiento de enfermedades autoinmunes.
UY36757A (es) Anticuerpos monoclonales murinos contra cd40 con actividad agonista mejorada
CR10308A (es) Anticuerpos monoclonales humanizados para el factor de crecimiento del hepatocito
CO2017000754A2 (es) Anticuerpo monoclonal anti-ctla4 o fragmento de unión a antígeno del mismo, y una composición farmacéutica del mismo
BR112017021245A2 (pt) Anticorpo anti-c-met e conjugado anticorpo anti- c-met-fármaco citotóxico e uso farmacêutico do mesmo
CO2019013669A2 (es) Anticuerpos anti-garp-tgf-β
PE20190970A1 (es) Anticuerpos anti-cd40 y sus usos
MX2018012473A (es) Agentes que reconocen el epitopo de clever-1 y usos de los mismos.
AR100944A1 (es) ANTICUERPOS ANTAGONISTAS DE INTERFERÓN a Y w
ECSP21052193A (es) Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r
SV2019005822A (es) Metodos para tratar el cáncer de próstata
CL2019001715A1 (es) Estructura cristalina de gremlina 1 y anticuerpo inhibidor.
MX2017001686A (es) Anticuerpos anti-ceramida.
MX2019010707A (es) Metodos para tratar y/o prevenir queratosis actinica.
CO2022001354A2 (es) Métodos para tratar o prevenir la atrofia muscular espinal
MX2021009789A (es) Dosificacion y administracion de anticuerpos anti-c5 para el tratamiento de miastenia gravis generalizada.
MX2019006597A (es) Terapia basada en células nk mejoradas.
CL2021002866A1 (es) Tratamiento de la cefalea usando anticuerpos anti-cgrp.
MX2020011377A (es) Metodos y composiciones para el tratamiento de urticaria cronica.
MX2022005245A (es) Regimen de dosificacion de anticuerpos anti-cd27 para el tratamiento de cancer.
MX2017015765A (es) Regimenes de dosificacion inmunoterapeutica que comprenden pomalidomida y un anticuerpo anti-cs1 para el tratamiento de cancer.
EA202190504A1 (ru) Способы лечения псориаза